AA amyloidosis: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = AA amyloidosis | |||
| synonyms = Secondary amyloidosis | |||
| field = [[Rheumatology]], [[Nephrology]] | |||
| symptoms = [[Proteinuria]], [[nephrotic syndrome]], [[kidney failure]], [[hepatomegaly]], [[splenomegaly]] | |||
| complications = [[Chronic kidney disease]], [[end-stage renal disease]] | |||
| onset = Variable, often years after chronic inflammation | |||
| duration = Chronic | |||
| causes = Chronic inflammatory conditions, such as [[rheumatoid arthritis]], [[inflammatory bowel disease]], [[chronic infections]] | |||
| risks = Chronic inflammatory diseases, [[familial Mediterranean fever]] | |||
| diagnosis = [[Biopsy]] showing amyloid deposits, [[serum amyloid A]] levels | |||
| differential = Other forms of [[amyloidosis]], [[multiple myeloma]] | |||
| treatment = Treat underlying condition, [[colchicine]], [[biologic therapy]] | |||
| prognosis = Variable, depends on underlying condition and organ involvement | |||
| frequency = Rare | |||
}} | |||
AA amyloidosis, also known as secondary amyloidosis, is a form of amyloidosis characterized by the accumulation of amyloid A protein in organs and tissues throughout the body. Amyloid A protein is an acute-phase reactant produced by the liver in response to inflammation. AA amyloidosis typically arises as a complication of chronic infectious or inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic infections. | AA amyloidosis, also known as secondary amyloidosis, is a form of amyloidosis characterized by the accumulation of amyloid A protein in organs and tissues throughout the body. Amyloid A protein is an acute-phase reactant produced by the liver in response to inflammation. AA amyloidosis typically arises as a complication of chronic infectious or inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic infections. | ||
==Etiology== | ==Etiology== | ||
The development of AA amyloidosis is closely linked to chronic inflammation. Inflammatory conditions lead to sustained high levels of serum amyloid A (SAA) protein, a precursor to amyloid A. Over time, the continuous production and deposition of SAA protein fragments in tissues form amyloid deposits, impairing organ function. | The development of AA amyloidosis is closely linked to chronic inflammation. Inflammatory conditions lead to sustained high levels of serum amyloid A (SAA) protein, a precursor to amyloid A. Over time, the continuous production and deposition of SAA protein fragments in tissues form amyloid deposits, impairing organ function. | ||
==Pathophysiology== | ==Pathophysiology== | ||
In AA amyloidosis, the amyloid deposits primarily consist of fibrils derived from the cleavage of SAA protein. These fibrils disrupt the normal architecture and function of affected organs. The kidneys are most commonly involved, leading to proteinuria and potentially progressive renal failure. However, the liver, spleen, heart, and gastrointestinal tract can also be affected. | In AA amyloidosis, the amyloid deposits primarily consist of fibrils derived from the cleavage of SAA protein. These fibrils disrupt the normal architecture and function of affected organs. The kidneys are most commonly involved, leading to proteinuria and potentially progressive renal failure. However, the liver, spleen, heart, and gastrointestinal tract can also be affected. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
The symptoms of AA amyloidosis are often nonspecific and vary depending on the organs involved. Common manifestations include: | The symptoms of AA amyloidosis are often nonspecific and vary depending on the organs involved. Common manifestations include: | ||
* Fatigue | |||
* Weight loss | |||
* Edema due to nephrotic syndrome | |||
* Hepatomegaly or splenomegaly | |||
* Cardiac arrhythmias or heart failure, if the heart is involved | |||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of AA amyloidosis involves a combination of clinical evaluation, laboratory tests, and histological examination. The presence of a chronic inflammatory condition, along with symptoms suggestive of organ involvement, may prompt further investigation for amyloidosis. Laboratory tests may show elevated levels of SAA protein. The definitive diagnosis is made by biopsy of an affected organ or abdominal fat pad, demonstrating amyloid deposits with specific staining properties. | Diagnosis of AA amyloidosis involves a combination of clinical evaluation, laboratory tests, and histological examination. The presence of a chronic inflammatory condition, along with symptoms suggestive of organ involvement, may prompt further investigation for amyloidosis. Laboratory tests may show elevated levels of SAA protein. The definitive diagnosis is made by biopsy of an affected organ or abdominal fat pad, demonstrating amyloid deposits with specific staining properties. | ||
==Treatment== | ==Treatment== | ||
Treatment of AA amyloidosis focuses on managing the underlying inflammatory condition to reduce the production of SAA protein. This may involve the use of anti-inflammatory medications, immunosuppressants, or biologic agents. In cases where renal function is significantly impaired, dialysis or kidney transplantation may be necessary. There is also ongoing research into therapies that can directly remove amyloid deposits or inhibit their formation. | Treatment of AA amyloidosis focuses on managing the underlying inflammatory condition to reduce the production of SAA protein. This may involve the use of anti-inflammatory medications, immunosuppressants, or biologic agents. In cases where renal function is significantly impaired, dialysis or kidney transplantation may be necessary. There is also ongoing research into therapies that can directly remove amyloid deposits or inhibit their formation. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis of AA amyloidosis varies depending on the extent of organ involvement and the effectiveness of treatment for the underlying inflammatory condition. Early diagnosis and aggressive management of the inflammatory disease can improve outcomes and slow the progression of organ damage. | The prognosis of AA amyloidosis varies depending on the extent of organ involvement and the effectiveness of treatment for the underlying inflammatory condition. Early diagnosis and aggressive management of the inflammatory disease can improve outcomes and slow the progression of organ damage. | ||
==See Also== | ==See Also== | ||
* [[Amyloidosis]] | |||
* [[Chronic inflammation]] | |||
* [[Nephrotic syndrome]] | |||
* [[Rheumatoid arthritis]] | |||
* [[Inflammatory bowel disease]] | |||
[[Category:Protein folding disorders]] | [[Category:Protein folding disorders]] | ||
[[Category:Kidney diseases]] | [[Category:Kidney diseases]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Latest revision as of 22:00, 3 April 2025
| AA amyloidosis | |
|---|---|
| Synonyms | Secondary amyloidosis |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Proteinuria, nephrotic syndrome, kidney failure, hepatomegaly, splenomegaly |
| Complications | Chronic kidney disease, end-stage renal disease |
| Onset | Variable, often years after chronic inflammation |
| Duration | Chronic |
| Types | N/A |
| Causes | Chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease, chronic infections |
| Risks | Chronic inflammatory diseases, familial Mediterranean fever |
| Diagnosis | Biopsy showing amyloid deposits, serum amyloid A levels |
| Differential diagnosis | Other forms of amyloidosis, multiple myeloma |
| Prevention | N/A |
| Treatment | Treat underlying condition, colchicine, biologic therapy |
| Medication | N/A |
| Prognosis | Variable, depends on underlying condition and organ involvement |
| Frequency | Rare |
| Deaths | N/A |
AA amyloidosis, also known as secondary amyloidosis, is a form of amyloidosis characterized by the accumulation of amyloid A protein in organs and tissues throughout the body. Amyloid A protein is an acute-phase reactant produced by the liver in response to inflammation. AA amyloidosis typically arises as a complication of chronic infectious or inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic infections.
Etiology[edit]
The development of AA amyloidosis is closely linked to chronic inflammation. Inflammatory conditions lead to sustained high levels of serum amyloid A (SAA) protein, a precursor to amyloid A. Over time, the continuous production and deposition of SAA protein fragments in tissues form amyloid deposits, impairing organ function.
Pathophysiology[edit]
In AA amyloidosis, the amyloid deposits primarily consist of fibrils derived from the cleavage of SAA protein. These fibrils disrupt the normal architecture and function of affected organs. The kidneys are most commonly involved, leading to proteinuria and potentially progressive renal failure. However, the liver, spleen, heart, and gastrointestinal tract can also be affected.
Clinical Presentation[edit]
The symptoms of AA amyloidosis are often nonspecific and vary depending on the organs involved. Common manifestations include:
- Fatigue
- Weight loss
- Edema due to nephrotic syndrome
- Hepatomegaly or splenomegaly
- Cardiac arrhythmias or heart failure, if the heart is involved
Diagnosis[edit]
Diagnosis of AA amyloidosis involves a combination of clinical evaluation, laboratory tests, and histological examination. The presence of a chronic inflammatory condition, along with symptoms suggestive of organ involvement, may prompt further investigation for amyloidosis. Laboratory tests may show elevated levels of SAA protein. The definitive diagnosis is made by biopsy of an affected organ or abdominal fat pad, demonstrating amyloid deposits with specific staining properties.
Treatment[edit]
Treatment of AA amyloidosis focuses on managing the underlying inflammatory condition to reduce the production of SAA protein. This may involve the use of anti-inflammatory medications, immunosuppressants, or biologic agents. In cases where renal function is significantly impaired, dialysis or kidney transplantation may be necessary. There is also ongoing research into therapies that can directly remove amyloid deposits or inhibit their formation.
Prognosis[edit]
The prognosis of AA amyloidosis varies depending on the extent of organ involvement and the effectiveness of treatment for the underlying inflammatory condition. Early diagnosis and aggressive management of the inflammatory disease can improve outcomes and slow the progression of organ damage.
